Peer-influenced content. Sources you trust. No registration required. This is HCN.

Blood AdvancesActivity of mRNA COVID-19 Vaccines in Patients with Lymphoid Malignancies

Publication: Blood Advances
Study Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.
Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.
Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls.

Related Article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with B-Cell Non-Hodgkin Lymphoma

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form